Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 28, 2014; 20(12): 3087-3099
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3087
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3087
Systemic therapy of hepatocellular carcinoma: Current status and future perspectives
Domenico Germano, Bruno Daniele, Oncology Unit, A.O. “G. Rummo”, 82100 Benevento, Italy
Author contributions: Germano D wrote the manuscript; Daniele B contributed to the final revision.
Supported by The consulting and lecture fees from Bayer, Daiichi Sankyo and Novartis to Daniele B
Correspondence to: Domenico Germano, MD, Oncology Unit, A.O. “G. Rummo”, Via dell’Angelo, 1, 82100 Benevento, Italy. domgerm@libero.it
Telephone: +39-82-457709 Fax: +39-82-457709
Received: September 30, 2013
Revised: November 10, 2013
Accepted: January 6, 2014
Published online: March 28, 2014
Processing time: 187 Days and 12.3 Hours
Revised: November 10, 2013
Accepted: January 6, 2014
Published online: March 28, 2014
Processing time: 187 Days and 12.3 Hours
Core Tip
Core tip: Many molecularly targeted agents that inhibit angiogenesis, epidermal growth factor receptor, and mammalian target of rapamycin are at different stages of clinical development in advanced hepatocellular carcinoma. Future research should continue to unravel the mechanism of hepatocarcinogenesis and to identify key relevant molecular targets for therapeutic intervention.